Intranasal Therapeutics, Inc. (ITI, Montvale, NJ, www.intranasal.com), has appointed Peter F. Young as president and chief executive officer.
Intranasal Therapeutics, Inc. (ITI, Montvale, NJ, www.intranasal.com), has appointed Peter F. Young as president and chief executive officer. Young was most recently the president and CEO of AlphaVax, a North Carolina-based biotechnology company. While at AlphaVax, Young grew that company from six to 75 employees and advanced its technology from the academic bench to human clinical trials.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Filter Sizing for Process Optimization in Life Sciences Sterile Filtration
April 24th 2025Bench-scale filterability studies play a critical role in optimizing sterile filtration in biopharmaceutical manufacturing. By guiding the selection and sizing of filters, these studies help streamline processes, improve scalability, and reduce costs. Through data-driven case studies, this paper highlights how the strategic use of pre-filters and membrane materials can maximize throughput and minimize filter fouling.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.